This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


GlaxoSmithKline plc

Drug Names(s): GW-406381

Description: The first dual-action COX-2 inhibitor, 406381, is designed to improve on existing drugs in its class. 406381 is able to treat two main types of pain - inflammatory and neuropathic - by acting both peripherally and centrally. Currently marketed COX-2 inhibitors have not been proven to be effective in neuropathic pain, like neuralgia. Initial clinical data indicate that 406381 penetrates the human brain more effectively than existing COX-2 inhibitors, and is therefore expected to lead to greater effectiveness across a range of pain types, such as osteo-arthritis, rheumatoid arthritis, back pain, and neuropathic pain.

406381 News

Pink Sheet ASK Filing Timeline

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug